Unleashing the future of healthcare.
Engineering biology is already shaping the world, and novel technologies such as antibody-based drugs, CAR-T therapies and mRNA vaccines are placing greater demand on the supply of high-quality gene-length DNA. The continued growth of these fields demands a breakthrough in gene synthesis technology. We’re developing the platform that will get researchers results faster, accelerating progress and empowering scientists to harness the full potential of engineering biology.
mRNA vaccines are faster to design and produce than other vaccine technologies. The first mRNA vaccines were approved for COVID-19, but many others are in development for an array of diseases, including influenza, RSV and tuberculosis, with further potential as a personalized cancer treatment. Rapid growth and investment in this developing field drive requirements for increased gene synthesis capacity and faster turnaround.
Monoclonal antibodies are the fastest-growing class of biotherapeutic. Over a thousand monoclonal antibody therapies are either in clinical use or being trialed for conditions including cancers, ulcerative colitis, Alzheimer’s disease and hemophilia. The rapid expansion of this proven therapeutic class supports higher throughput screening and optimization of antibody sequences, all requiring rapid, high-quality gene synthesis.
Protein engineering is set for rapid expansion as AI tools accelerate functional protein design. Applications across pharmaceuticals, agriculture, industrial chemistry and materials require extensive iterative development and testing, driving the need for high-throughput synthesis of gene-length DNA.
Optimizing the Design-Build-Test-Learn (DBTL) cycle to scale engineering biology
A deep dive into the opportunities afforded by engineering biology alongside challenges in realizing its potential, including advantages and limitations of common DNA synthesis workflows and recent developments that aim to accelerate this process.Read the whitepaper